XNASINMB
Market cap99mUSD
Dec 24, Last price
4.49USD
1D
-1.32%
1Q
-7.61%
IPO
-42.29%
Name
INmune Bio Inc
Chart & Performance
P/E
—
P/S
642.29
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.89%
Rev. gr., 5y
0.00%
Revenues
155k
-58.56%
Net income
-30m
L+4.75%
CFO
-12m
L-47.19%
Earnings
Mar 26, 2025
Profile
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 155 -58.56% | 374 106.63% | 181 1,558.12% | ||||||
Cost of revenue | 29,896 | 26,325 | 29,334 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (29,741) | (25,951) | (29,153) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 1,348 | (29,153) | |||||||
Tax Rate | |||||||||
NOPAT | (29,741) | (27,299) | |||||||
Net income | (30,008) 4.75% | (28,647) -5.58% | (30,340) 150.76% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 775 | 729 | 81,406 | ||||||
BB yield | -0.38% | -0.64% | -49.48% | ||||||
| Debt | |||||||||
Debt current | 10,159 | 5,087 | 72 | ||||||
Long-term debt | 913 | 10,836 | 15,938 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 550 | 199 | |||||||
Net debt | (24,776) | (36,230) | (58,800) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (11,980) | (22,686) | (28,504) | ||||||
CAPEX | (15,000) | ||||||||
Cash from investing activities | (15,000) | ||||||||
Cash from financing activities | (4,225) | 729 | 96,357 | ||||||
FCF | (22,957) | (30,262) | (3,802) | ||||||
| Balance | |||||||||
Cash | 35,848 | 52,153 | 74,810 | ||||||
Long term investments | |||||||||
Excess cash | 35,840 | 52,134 | 74,801 | ||||||
Stockholders' equity | (121,004) | (91,695) | (63,696) | ||||||
Invested Capital | 169,699 | 167,659 | 159,354 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 17,981 | 17,927 | 16,131 | ||||||
Price | 11.26 77.60% | 6.34 -37.84% | 10.20 -40.77% | ||||||
Market cap | 202,464 78.13% | 113,659 -30.92% | 164,531 -20.30% | ||||||
EV | 177,688 | 77,429 | 105,731 | ||||||
EBITDA | (29,741) | (25,951) | (29,153) | ||||||
EV/EBITDA | |||||||||
Interest | 1,348 | ||||||||
Interest/NOPBT | |||||||||